Tag Archives | pharmaceuticals

More changes at Jubilant?

Jubilant Organosys appears to be taking one more step in transforming itself into a pharmaceutical company. The company is looking at selling its industrial and performance products division and expects to realise Rs3.0-3.5bn from the sale, says this report in today’s Economic Times. There was no official confirmation on this from the company. The division, […]

Continue Reading

Not so fine anymore?

News is slowly trickling in of Indian pharmaceutical and fine chemical companies shutting down facilities that were acquired with great zeal during the 2005-08 overseas acquisition drive. Shasun has decided to shut its facility at Newbie in Scotland and is reportedly shifting manufacturing to other locations in the US, the UK and India. The Newbie […]

Continue Reading

Sign of things to come?

The big news today is Daiichi Sankyo’s acquisition of a controlling stake in Ranbaxy, India’s largest pharmaceutical company, for $4.6bn. Analysts have been quick to predict many more such deals which will see international pharma majors entering the generic space. Indian generic players have been steadily expanding their presence in markets in the developed world, […]

Continue Reading

Struggling with Reach

Are Indian chemical companies ready for Reach? Apparently not, says this report in today’s Mint. The problem appears to be not only lack of awareness about the EU programme for registration, evaluation and authorisation of chemicals (Reach) but also a shortage of labs certified for good laboratory practices (GLP), a standard developed by the OECD. […]

Continue Reading

Pharma still keen on M&As

The Indian pharmaceutical sector is keeping the M&A fire burning with six deals concluded last month, up from eight in the January-March period. The list includes Jubilant Organosys’ $255m acquisition of US-based DRAXIS Health and the $218m buyout of Dabur Pharma by Fresenius Kabi. Indian companies are expected to continue scouting for overseas assets although […]

Continue Reading

Matrix mulls Docpharma sale

Have Indian fine chemical and pharma companies been too hasty in their global acquisitions? I had been hearing talk of some companies running into integration problems or having second thoughts on perceived benefits of their acquisitions. But today’s report that Matrix Labs is exploring sale of Docpharma suggests that there is some basis to all […]

Continue Reading
world%20crams.JPG

Testing times for CRAMS

Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country’s strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m, and expects it to expand by 40% in 2008. It estimates the market for outsourcing […]

Continue Reading

Cashing in on APIs

How big is the opportunity for Indian active pharmaceutical ingredients’ (API) manufacturers? Here is an estimate presented by Satish Khanna, group president, API, Lupin Ltd, at the Speciality Chemicals Conclave in Mumbai last week. To develop his estimate, Khanna first examined the health care spend in India vis-à-vis developing and developed countries. The per capita […]

Continue Reading

CRAMs comes with challenges

India’s success in the global custom research and manufacturing services space (CRAMS) is well documented. And the untapped potential is huge especially as western pharmaceutical companies remain under pressure to cut costs. According to one estimate, the global manufacturing outsourcing opportunity is likely to grow from US$20bn in 2006 to US$31bn in 2010. The global […]

Continue Reading

CRAMS: still going strong

Indian companies in the contract research and manufacturing services (CRAMS) domain appear to be doing well as is reflected in the stock market performance of these companies. The list includes Divi’s Laboratories, Dishman Pharmaceuticals & Chemicals, Nicholas Piramal, Shasun Chemicals & Drugs, and Jubilant Organosys This report in today’s Economic Times highlights that CRAMS companies’ […]

Continue Reading